Skip to content

Side by side

ACE-031 vs Tesamorelin

Both are discussed for muscle & performance. What this site records about each, side by side. Every figure is on the compound's own page with the source it came from.

ACE-031 and Tesamorelin compared on what BioAlmanac records.
 ACE-031Tesamorelin
What it isA myostatin trap that reached phase 2 in Duchenne muscular dystrophy and was stopped there. The muscle effects were real but never reached significance; the reason it stopped was nosebleeds and spider veins.A GHRH analogue approved by the FDA for reducing excess visceral fat in HIV-associated lipodystrophy. The only compound in this category with completed phase 3 trials.
EvidenceHow much human evidence exists, not how well it works.Early human trialsApproved for another indication
Regulatory statusReviewed 2026-09-01Never approved anywhere. Development was halted in 2011 on safety grounds and permanently discontinued in 2013. Prohibited in sport at all times by WADA as a myostatin inhibitor. Material sold as a research chemical is not the clinical product and carries none of the trial's monitoring.Approved by the FDA as a prescription medicine for reducing excess visceral abdominal fat in adults with HIV-associated lipodystrophy. It is not approved for body composition, athletic performance or anti-ageing use, and material sold as a research chemical is not the approved product.
RoutesSubcutaneousSubcutaneous
Half-lifeNot recorded0.4 hours
Cheapest per mgVials only, read from vendors' own listings and dated on the price index.$69.99/mg$2.35/mg
Median per mg$150.00/mg$6.50/mg
Vendors with a price551
Storage once mixedRefrigerated at 2–8 °C. Proteins of this size are more fragile than short peptides — avoid shaking, which denatures them.Refrigerated at 2–8 °C. The approved product is intended for use shortly after reconstitution rather than stored for weeks.

Compare two other compounds · The full price index

This page is educational. It describes what published research reports, not what you should do. Peptides discussed here are largely not approved for human use, and nothing on BioAlmanac is medical advice. Nothing here ranks these two against each other. A table can show that one has more human evidence behind it or costs less per milligram; neither of those is a recommendation, and the right comparison for any person is one their doctor makes with them.